Best Immunotherapy Companies in New York, United States
The 62 best Immunotherapy companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Immunovant.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in New York
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Immunovant Provider of therapeutics solutions for treating autoimmune diseases 29Funding top 16%News top 45%Moat top 48%Tech bottom 48% All 7 signals ▾Fundingtop 16% Newstop 45% Moattop 48% Techbottom 48% Growthbottom 47% Globalbottom 41% Marketbottom 25% Funding: Raised $685M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) News: 7 BI events in 12 mo (of 46 tracked, 7 types) · -50% YoY rank vs industry peers · Fliar Intelligence Index 29/100 | $685M | 17 mo ago | 1 | — | Public | — | — |
| 2 | IRX Therapeutics Developing innovative cell therapies for advanced cancer and autoimmune diseases | $190M | 105 mo ago | 29 | — | Acqui-Hired | — | — |
| 3 | Selecta Biosciences Developer of nanoparticle immunomodulatory drugs for treating multiple diseases | $155M | 70 mo ago | 67 | — | Public | 957 patents Tolerogenic nanocarrier delivery systems for immune‑tolerant protein therapeutics | — |
| 4 | Caladrius Biosciences Developer of cell therapy based drugs for coronary microvascular dysfunction, diabetes, cancer and limbic… | $128M | 65 mo ago | 53 | — | Public | — | — |
| 5 | Elevation Oncology Developer of precision medicine for the treatment of cancer | $98M | 67 mo ago | 29 | Shawn Leland Founder | Public | 5 patents Therapeutic anti‑ERBB3 (HER3) monoclonal antibodies for NRG1‑fusion driven cancers | — |
| 6 | Mustang Bio Developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment | $95M | 32 mo ago | 80 80 → 43 (-46%) · sector median -32% | Manuel Litchman CEO | Public | — | — |
| 7 | Y-mAbs Therapeutics Provider of antibodies-based products targeting GD2 and B7H3 tumor antigens. | $90M | 102 mo ago | 100 100 → 59 (-41%) · sector median -32% | — | Acquired | — | — |
| 8 | Promontory Therapeutics Developer of immunotherapeutics for the treatment of cancer | $72M | 54 mo ago | 17 17 → 11 (-35%) · sector median -32% | Matthew Price Co-Founder & COO | Series A | — | — |
| 9 | Checkpoint Therapeutics Developer of immunotherapy and targeted cancer treatments to improve healthcare access | $58M | 126 mo ago | 24 | — | Acquired | — | — |
| 10 | Fortress Biotech Developing novel immunotherapy agents for cancer and inflammatory diseases | $55M | 99 mo ago | 187 | Lindsay Rosenwald CEO | Public | — | — |
| 11 | Adendra Therapeutics Developer of cell therapies for cancers and autoimmune diseases | $53M | 54 mo ago | 1 | Caetano E Sousa Co-Founder | Series A | — | — |
| 12 | Codagenix Developer of live-attenuated viral vaccines using proprietary SAVE technology 62Patents top 19%Moat top 21%Innovation top 24%Talent top 28% All 9 signals ▾Patentstop 19% Moattop 21% Innovationtop 24% Talenttop 28% Fundingtop 30% Marketbottom 49% Globalbottom 42% Techbottom 38% Newsbottom 27% Patents: 127 patents matched (strict assignee match) · 91 filings since 2022 vs 36 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 127 patents rank vs industry peers · Fliar Intelligence Index 62/100 | $47M | 14 mo ago | 41 | — | Series B | 127 patents Codon-deoptimized viral genome platforms for live-attenuated vaccines and immunotherapies | — |
| 13 | Panacela Labs Development and commercialization of drugs for the treatment of oncology or other diseases. | $40M | 126 mo ago | 1 | Yakov Kogan CEO | Deadpooled | 32 patents Immuno‑oncology therapeutics: TLR agonist gene vectors and Myc‑targeting small molecules. | — |
| 14 | Tactiva Therapeutics Innovative cancer immunotherapy company developing next-generation adoptive T cell therapies | $35M | 90 mo ago | 4 | — | Series A | — | — |
| 15 | IN8Bio Provider of immune based therapies for the treatment of cancer 50Funding top 27%Patents top 32%Moat top 38%Innovation top 39% All 10 signals ▾Fundingtop 27% Patentstop 32% Moattop 38% Innovationtop 39% Techtop 41% Newstop 42% Growthtop 45% Talentbottom 41% Marketbottom 39% Globalbottom 36% Funding: Raised $35.0M across 5 rounds · 5 rounds over 6 yrs (0.8/yr) Patents: 33 patents matched (strict assignee match) · 25 filings since 2022 vs 8 in 2017-21 rank vs industry peers · Fliar Intelligence Index 50/100 | $35M | 6 mo ago | 31 31 → 25 (-19%) · sector median -32% | William Ho Founder & CEO | Public | 33 patents Engineered gamma‑delta T‑cell CAR immunotherapies and targeted peptide cancer treatments | — |
| 16 | RenBio Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases | $29M | 22 mo ago | 10 10 → 8 (-20%) · sector median -32% | David Ho Co-Founder | Series A | 11 patents Patents concentrated in health & consumer products | — |
| 17 | TG Therapeutics Developer of treatments for B-cell malignancies and autoimmune diseases | $25M | 171 mo ago | 264 264 → 542 (+105%) · sector median -32% | — | Public | 1,872 patents Patents concentrated in chemistry & materials | — |
| 18 | Actinium Pharma Developer of radiation conjugates antibodies for the treatment of cancer | $18M | 69 mo ago | 22 | — | Public | — | — |
| 19 | Vaccinex Deveeloper of therapeutics to treat cancer and neurologic diseases | $15M | 26 mo ago | 41 41 → 28 (-32%) · sector median -32% | — | Public | 576 patents Semaphorin‑4D inhibition and CCR8 antibody therapeutics for neurodegeneration, cognition, and atherosclerosis | — |
| 20 | Adjuvance Technologies Involved in vaccine adjuvant design and manufacturing. | $13M | 73 mo ago | 20 | — | Series A | 15 patents Vaccine adjuvant development using triterpene saponin synthesis and analogues | — |
| 21 | Caelum Biosciences Chimeric fibril-reactive monoclonal antibody (mAb) for the treatment of AL Amyloidosis | $10M | 104 mo ago | — | Michael Spector Co-Founder & CEO | Acqui-Hired | — | — |
| 22 | United Biomedical Discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious… | $9M | 345 mo ago | 42 | Nean Hu Co-Founder | Series A | 314 patents Peptide-based vaccines and immunotherapies for animal and human disease treatment | — |
| 23 | Innovimmune Innovating immunotherapies for cancer, autoimmune diseases, and chronic inflammation | $7M | 168 mo ago | — | Anderson Gaweco President & CEO | Funding Raised | — | — |
| 24 | PIN Pharma US-based, preclinical-stage biopharma, developing a broad-base immunomodulatory cancer therapy | $7M | — | 1 | — | Series A | — | — |
| 25 | Aethon Therapeutics Developer of immunotherapies for cancer treatment | $6M | 21 mo ago | 7 | Benjamin Neel Co-Founder | Series A | — | — |
| 26 | Helocyte Developing immunotherapies for cancer and infectious diseases, particularly cytomegalovirus | $4M | 115 mo ago | 2 | — | Funding Raised | — | — |
| 27 | Immune Pharmaceuticals Developer of therapeutic agents for the treatment of immunologic and inflammatory diseases | $4M | 103 mo ago | 9 | — | Public | — | — |
| 28 | Intrommune Developing oral mucosal immunotherapy toothpaste for food allergy management | $3M | 30 mo ago | 15 | Michael Nelson Founder & CEO | Series A | — | — |
| 29 | For-Robin Therapeutics Developing cancer therapeutics, driven by personal mission, for clinical trials | $3M | 87 mo ago | 2 | Kate Rittenhouse Founder & President | Funding Raised | — | — |
| 30 | POP BIO Developer of nanomedicines to treat oncology and infectious diseases | $2M | 13 mo ago | 5 | Jonathan Smyth Co-Founder | Funding Raised | — | — |
| 31 | AV Therapeutics Specialty company developing cancer therapeutics and immunotherapeutic vaccines | $2M | 145 mo ago | — | Abe Mittleman CEO | Deadpooled | 1,872 patents Patents concentrated in chemistry & materials | — |
| 32 | Akari Therapeutics Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. | $2M | 6 mo ago | 5 | Ray Prudo Chairman | Public | — | — |
| 33 | Cynvec Developing innovative viral immunotherapies, pioneering cancer treatment using the body's immune system | $2M | 71 mo ago | 3 | Daniel Wilds ex-Acting President and CEO | Seed | — | — |
| 34 | Mercia Pharma Vaccine in combination with adjuvants for autoimmune, CNS, respiratory and infectious diseases | $2M | 203 mo ago | — | Peter Blackburn President and Founder | Funding Raised | — | — |
| 35 | MimiVax Disrupting cancer with innovative immunotherapies aimed at increasing patient survival rates | $2M | 11 mo ago | 3 | — | Series A | 2 patents Therapeutic anti‑survivin antibodies for cancer treatment | — |
| 36 | Concarlo Developer of therapies for treating breast cancer | $1M | 71 mo ago | 7 | LisaMarie Casey Co-Founder | Seed | 9 patents BRK peptide inhibitors for therapeutic cancer applications | — |
| 37 | Synthis Therapeutics Developer of therapeutics to treat cancer | $1M | 21 mo ago | 3 | Dori Karyat Founder & CEO | Funding Raised | — | — |
| 38 | PyrOjas Developer of autologous whole-cell vaccine for durable cancer control | $748K | 21 mo ago | — | Archis B Founder & CEO | Funding Raised | 3 patents Immunotherapy pharmaceutical compositions for cancer treatment | — |
| 39 | Nomocan Pharmaceuticals Developing first-in-class targeted monoclonal antibody therapies for aggressive cancers | $740K | 136 mo ago | 4 | Ehsan Yazdi Founder & CEO | Seed | — | — |
| 40 | Vybion Intrabody therapeutics for neurodegenerative diseases, targeting intracellular events | $600K | 193 mo ago | 5 | Lee Henderson CEO | Funding Raised | 29 patents Intracellular single-chain antibody therapeutics for degrading mutant huntingtin protein | — |
| 41 | Manhattan BioSolutions Developer of immunotherapies for treating cancer | $546K | 69 mo ago | — | Borys Shor Co-Founder & CEO | Funding Raised | — | — |
| 42 | MiNK Therapeutics Developer of T cell therapies for cancer and other immune-mediated diseases | $306K | 13 mo ago | 37 37 → 31 (-16%) · sector median -32% | Jennifer Buell CEO | Public | — | — |
| 43 | Ichor Biologics Developer of monoclonal antibodies for treating infectious and inflammatory diseases | $300K | 85 mo ago | 21 | Raymond Alvarez Co-Founder & CEO | Funding Raised | 6 patents Therapeutic and diagnostic antibodies targeting Andes hantavirus | — |
| 44 | Loki Therapeutics Developer of immune-therapeutic solutions for the treatment of cancer diseases | $295K | 24 mo ago | 1 | — | Funding Raised | — | — |
| 45 | Hepione Therapeutics Developer of immuno-therapeutics for opioid overdose and cancer | $262K | 68 mo ago | — | Joey Verdi Co-Founder | Funding Raised | — | — |
| 46 | Humane Genomics Developer of cancer therapeutics using the oncolytic virus | $125K | 16 mo ago | 8 | Chad Moles Co-Founder & CSO | Seed | 10 patents Engineered oncolytic viruses and modular viral genome platforms for targeted cancer therapy | — |
| 47 | Brooklyn ImmunoTherapeutics Developer of cytokine-based therapeutics for treating cancer | — | 51 mo ago | 14 14 → 9 (-36%) · sector median -32% | Mark Leuchtenberger CEO & President | Late Stage | 11 patents Combination checkpoint inhibitor and multi‑cytokine biologic therapies for cancer immunotherapy | 1 launch |
| 48 | BeyondSpring Pharma Innovative biopharmaceutical company focused on cancer therapies and targeted protein degradation | — | 104 mo ago | 64 | — | Public | — | — |
Top 12 Immunotherapy companies in New York
#1
Public · New York City, New York · founded 2020 · 31 employees$35Mraised▾
Provider of immune based therapies for the treatment of cancer. The company offers its proprietary technology and develop genetically modified gamma-delta (γδ) T cells for targeting cold, low mutation cancers cell. It offers pipeline of drug candidates which include INB-200 for glioblastoma, INB-100 for leukemia, INB-400 for solid tumors, and others.
- Dec 2025Post IPO$20.1M
- Oct 2024Post IPO$12.4M
- Dec 2023Post IPO$14.4M
- Sep 2020Series C$35M
#2
Public · New York City, New York · founded 2016 · 1 employees$685Mraised▾
Provider of therapeutic solutions to treating autoimmune diseases. The company's product line include, IMVT-1401, is a human recombinant anti-FcRn monoclonal antibody that is being developed with a focus on patient needs and a range of autoimmune diseases. The candidate is meant for diseases like Myasthenia Gravis, and Graves’ Ophthalmopathy.
- Jan 2025Post IPO$450M
- Jan 2022Post IPO—
- Aug 2021Post IPO$200M
- Oct 2019Conventional Debt$35M
#3
Series B · Stony Brook, New York · founded 2011 · 41 employees$47.1Mraised▾
Developer of live-attenuated viral vaccines using proprietary SAVE technology. The SAVE platform relies on synthetic biology and re-design of the target virus' entire genome to yield a vaccine strain. All pipeline vaccines are currently in preclinical stages targeting seasonal influenza, dengue virus (DEV), respiratory syncytial virus (RCV), and pandemic influenza.
- Apr 2025Grant (prize money)$4.4M
- Oct 2023Grant (prize money)$10M
- Feb 2023Series B$25M
- Jul 2020Grant (prize money)$4.8M
#4
Public · New York City, New York · founded 2005 · 5 employees$2.4Mraised▾
Developer of therapeutics for autoimmune and inflammatory diseases by targeting the complement system. Its lead candidate is Nomacopan is being evaluated for four therapeutic areas which include bullous pemphigoid (BP), a severe blistering skin disease, thrombotic microangiopathy, AMD, and asthma. It is also developed compounds that inhibit the leukotriene system such as thromboxane A2.
- Dec 2025Post IPO—
- Mar 2025Post IPO$7.6M
- Dec 2023Post IPO—
- Jul 2021Post IPO$12.3M
#5
Series A · New York City, New York · founded 2016 · 10 employees$29.2Mraised▾
Developer of antibody-based therapeutic solutions for the treatment of cancer & inflammatory diseases. The company's proprietary MYO technology involves in the development of antibody therapeutic that helps in treating rare diseases, viral infections, autoimmune diseases, and more by using DNA blueprint & antibody factory.
- Aug 2024Series A$5.2M
- Jan 2021Series A$24M
- Jul 2016Grant (prize money)$3.4M
#6
Series A · Buffalo, New York · founded 2012 · 3 employees$1.6Mraised▾
Disrupting cancer with innovative immunotherapies aimed at increasing patient survival rates. It is a biopharmaceutical company focused on developing novel immunotherapies for cancer treatment. Their lead product, SurVaxM, is a peptide-based immunotherapeutic vaccine targeting survivin, a protein overexpressed in many cancer cells. This approach stimulates the immune system to recognize and attack cancer cells while sparing healthy tissue. They are conducting clinical trials to evaluate the safety and efficacy of SurVaxM for glioblastoma, multiple myeloma, neuroendocrine tumors and pediatric brain tumors. The company leverages its proprietary survivin-targeting technology to explore new ways of stimulating the immune system to fight cancer cells. They are committed to improving outcomes and quality of life for those suffering from devastating diseases. The company collaborates with leading clinicians and scientists to deliver on the promise of SurVaxM and other products to improve the lives of patients battling cancer.
- Jul 2025Series A$500K
- Jan 2025Grant (prize money)$409.6K
- Jan 2024Series A—
- Oct 2023Conventional Debt$5.8M
#7
Funding Raised · Buffalo, New York · founded 2015 · 5 employees$2.5Mraised▾
Developer of nanomedicines to treat oncology and infectious diseases. The company has two patented porphyrin-phospholipid (PoP) liposome technologies which include a spontaneous nanoliposome antigen particleization (SNAP) platform for immunogenic vaccines and chemophototherapy (CPT) using PoP liposomes.
- May 2025Grant (prize money)$1.9M
- Feb 2025Grant (prize money)$600K
#8
Public · New York City, New York · founded 2015 · 80 employees$95Mraised▾
Mustang Bio is a developer of CAR-T cell therapy for brain cancer and acute myeloid leukemia treatment. Its drug pipeline includes engineered Chimeric Antigen Receptor & T-cells (CAR-T) targeting interleukin 13 Receptor α2 which is overexpressed on the surface of glioblastoma (GBM) cells (Phase 1); and CAR-T targeting CD123, which is overexpressed on the surface of Acute Myeloid Leukemia (AML) cells (Phase 1). The company also has sponsored a preclinical research agreement in place with COH to develop additional CAR-T cell products.
- Oct 2023Post IPO$4.7M
- Sep 2021Grant (prize money)$2M
- Aug 2019Grant (prize money)$9.3M
- Apr 2019Conventional Debt$15M
#9
Series A · New York City, New York · founded 2022 · 7 employees$6Mraised▾
Developer of immunotherapies for cancer treatment. It offers antibodies in combination with targeted covalent inhibitors of RAS, EGFR, and other cancer-associated mutations to selectively kill drug-resistant cancer cells. It is based on HapImmune platform that activate T cells that will kill tumor cells.
- Sep 2024Grant (prize money)$499.9K
- Apr 2023Grant (prize money)$499.5K
- Dec 2022Series A$6M
#10
Public · Rochester, New York · founded 1998 · 41 employees$15.1Mraised▾
Deveeloper of therapeutics to treat cancer and neurologic diseases. The company’s lead drug candidate, pepinemab, blocks SEMA4D and has the potential to increase immune activity against tumors and to reprogram underlying pathogenic immune mechanisms that amplify damage in chronic neurological disorders such as Alzheimer’s and Huntington’s disease.
- Mar 2024Post IPO$1.8M
- Feb 2024Post IPO$3.7M
- Jan 2022Post IPO$6.6M
- Sep 2020Post IPO$2M
#11
Public · New York City, New York · founded 2017 · 37 employees$306.5Kraised▾
Developer of T cell therapies for cancer and other immune-mediated diseases. The company has engineered iNKT cell therapies and bispecific iNKT cell engages for the treatment of solid tumors, multiple myeloma, GvHD, and others.
- May 2025Grant (prize money)$306.5K
#12
Funding Raised · New York City, New York · founded 2017 · 3 employees$1.4Mraised▾
Synthis Therapeutics is developing therapeutics to treat cancer by stimulating the immune system. The company is developing therapeutics that inhibit the immunosuppressive pathways such as TGF-β pathway to treat cancer.
- Sep 2024Grant (prize money)$579K
- Jun 2023Grant (prize money)$299.9K
- Aug 2019Grant (prize money)$510K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
How research on Immunology & Immunotherapy is moving in the United States
A read on the academic research around Immunology & Immunotherapy — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 13,913 United States-affiliated papers.
- Dana-Farber Cancer Institute608
- The University of Texas MD Anderson Cancer Center559
- Harvard University524
- Cornell University416
- Brigham and Women's Hospital408
- Immune system88→1414
- Tumor microenvironment30→481
- Cancer41→483
- Cancer immunotherapy35→460
- T cell23→340
- Immune system205→2094
- Cancer86→884
- Oncology71→760
- Internal medicine109→672
- Tumor microenvironment72→632
- Immune system67→663
- Cancer40→389
- Oncology24→257
- Disease16→242
- Clinical trial11→209
Where immunology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing immunology patents in the United States
United States immunology patent filing is accelerating — 10,389 filings from 4,528 assignees (2016–2025), led by UNIV California, Memorial Sloan Kettering Cancer , US Health; annual filings 785→970.
- UNIV California399
- Memorial Sloan Kettering Cancer 350
- US Health315
- UNIV Texas296
- Iovance Biotherapeutics284
- Abbvie270
- UNIV Pennsylvania237
- DANA Farber Cancer INST222
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.